ODM 106Alternative Names: ODM-106
Latest Information Update: 25 Mar 2017
At a glance
- Originator Orion
- Mechanism of Action GABA B receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Essential tremor
Most Recent Events
- 27 Jan 2016 Discontinued - Phase-I for Essential tremor (In volunteers) in Germany (PO) (Orion pipeline, January 2016)
- 01 Jan 2015 Preclinical trials in Essential tremor in Finland (PO) before January 2015